NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
Inhibrx Biosciences, Inc
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
ImmunityBio, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University of Pittsburgh
Dana-Farber Cancer Institute